You are here

Article Text

Article menu
Download PDFPDF
Letter
Macular infarction after intravitreal amikacin: mounting evidence against amikacin
  1. G Galloway,
  2. A Ramsay,
  3. K Jordan,
  4. A Vivian
  1. Department of Ophthalmology, West Suffolk Hospital, Bury St Edmunds, IP33 2QZ, UK
  1. Correspondence to: Mr Gavin Galloway; gavgal{at}doctors.org.uk

https://doi.org/10.1136/bjo.86.3.359

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Retinal toxicity attributable to intravitreal use of aminoglycosides for endophthalmitis has been reported. Campochiaro and Conway reported 101 cases of retinal damage due to intravitreal aminoglycosides.1 Amikacin, an aminoglycoside, is in widespread use in the United Kingdom for the treatment of Gram negative organisms in endophthalmitis. We report a case of macular toxicity following the use of intravitreal amikacin for postoperative endophthalmitis, outline mechanisms of retinal toxicity, and offer alternatives to amikacin. We believe that enough evidence now exists to support a change in the current Royal College of Ophthalmologists' endophthalmitis treatment guidelines that are based on the Endophthalmitis Vitrectomy Study.2

    Case Report

    A 69 year old white woman presented 1 day after uneventful right phacoemulsification and intraocular lens implantation with a vision of …

    View Full Text